Helix BioPharma Corp.
TSX:HBP.TOBiotechnology
-$0.07 today
- Market cap
- $65.69M
- Beta
- -0.29
- P/E (TTM)
- -32.6
- EPS (TTM)
- -$0.04
Volume 0.00M
Average 0.00M
HBP.TO Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Helix BioPharma Corp.TSX: HBP.TO
Net Debt · Q3 FY2026 · quarter ended Apr 2026
Net debt remains negative
Q3 FY2026 net debt was -CA$2.48M, compared with -CA$715K a year earlier.
Context
- Net debt amounted to 11.6% of total assets at the end of Q3 FY2026, down 59.2 pp from a year earlier.
- Net debt increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net debt keeps falling in the next quarterly balance sheet after a -247.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
CAD · from the balance sheet
- Latest · FY2025
- 270K CAD
- Year-over-year change
- +125.0%
- 4-year CAGR
- +54.8%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-07-31 | 270K | +125.0% |
| FY2024 | 2024-07-31 | (1.08M) | -33.8% |
| FY2023 | 2023-07-31 | (808K) | -3.1% |
| FY2022 | 2022-07-31 | (784K) | -1768.1% |
| FY2021 | 2021-07-31 | 47K | — |
Net Debt vs competitors
How HBP.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -247.3% is the lowest of 5, against a peer median of -25.2%.
- Net debt amounts to 11.6% of total assets for HBP.TO, versus a peer median of 56.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $31.63M USD | -31.3% | -20.8% | 24.1% | |
| Apr 2026 | CA$1.4M CAD | -48.9% | — | 91.2% | |
| Apr 2026 | -CA$2.48M CAD | -247.3% | — | 11.6% | |
MSCL.TOSatellos Bioscience Inc. | Mar 2026 | -$18.71M USD | +43.4% | — | 24.9% |
| Mar 2026 | -CA$27.56M CAD | -19.1% | — | 87.7% | |
| Peer median (excluding HBP.TO) | — | -25.2% | -20.8% | 56.3% | |
Competitors are the stored peer set for HBP.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Helix BioPharma Corp.
TSX:HBP.TO
Intrinsic Alpha fair value
Locked
Current Price
$0.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.